Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adverum Biotechnologies Inc (ADVM)

Adverum Biotechnologies Inc (ADVM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 92,061
  • Shares Outstanding, K 22,077
  • Annual Sales, $ 1,000 K
  • Annual Income, $ -130,930 K
  • EBIT $ -208 M
  • EBITDA $ -207 M
  • 60-Month Beta 0.87
  • Price/Sales 92.06
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 279.88% (-5.25%)
  • Historical Volatility 20.67%
  • IV Percentile 72%
  • IV Rank 44.64%
  • IV High 607.08% on 04/22/25
  • IV Low 16.01% on 09/09/25
  • Expected Move (DTE 14) 0.64 (14.96%)
  • Put/Call Vol Ratio 18.72
  • Today's Volume 631
  • Volume Avg (30-Day) 532
  • Put/Call OI Ratio 2.11
  • Today's Open Interest 19,130
  • Open Int (30-Day) 17,840
  • Expected Range 3.62 to 4.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.24
  • Number of Estimates 2
  • High Estimate -0.34
  • Low Estimate -2.14
  • Prior Year -1.96
  • Growth Rate Est. (year over year) +36.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.99 +6.73%
on 11/25/25
4.36 -2.29%
on 11/10/25
-0.03 (-0.70%)
since 11/05/25
3-Month
2.87 +48.43%
on 09/17/25
5.75 -25.91%
on 10/02/25
+0.74 (+21.02%)
since 09/05/25
52-Week
1.78 +139.33%
on 05/15/25
6.12 -30.39%
on 12/09/24
-1.43 (-25.13%)
since 12/05/24

Most Recent Stories

More News
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly

REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And Done...

ADVM : 4.26 (+2.16%)
Halper Sadeh LLC Encourages BRNS, FITB, ADVM, HBAN Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

FITB : 45.42 (-0.09%)
ADVM : 4.26 (+2.16%)
HBAN : 16.90 (-1.17%)
BRNS : 0.7213 (+0.04%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOUS, ADVM, HBAN, and COMP

NEW YORK , Nov. 19, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

COMP : 10.32 (-0.77%)
ADVM : 4.26 (+2.16%)
HOUS : 14.10 (-0.63%)
HBAN : 16.90 (-1.17%)
Adverum Biotechnologies: Q3 Earnings Snapshot

Adverum Biotechnologies: Q3 Earnings Snapshot

ADVM : 4.26 (+2.16%)
HALPER SADEH LLC ENCOURAGES ADVM, PLYM, RNA SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

ADVM : 4.26 (+2.16%)
RNA : 71.63 (+0.13%)
PLYM : 21.87 (-0.18%)
ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

ADVM : 4.26 (+2.16%)
ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

ADVM : 4.26 (+2.16%)
ADVM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Adverum Biotechnologies, Inc. Is Fair to Shareholders

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

ADVM : 4.26 (+2.16%)
Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Adverum Biotechnologies,...

ADVM : 4.26 (+2.16%)
LLY : 1,010.31 (-0.41%)
Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Adverum Biotechnologies,...

ADVM : 4.26 (+2.16%)
LLY : 1,010.31 (-0.41%)

Business Summary

Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum's core capabilities include clinical development,...

See More

Key Turning Points

3rd Resistance Point 4.44
2nd Resistance Point 4.36
1st Resistance Point 4.31
Last Price 4.26
1st Support Level 4.18
2nd Support Level 4.10
3rd Support Level 4.05

See More

52-Week High 6.12
Fibonacci 61.8% 4.46
Last Price 4.26
Fibonacci 50% 3.95
Fibonacci 38.2% 3.44
52-Week Low 1.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar